The role of white and grey matter and meningeal inflammation in multiple sclerosis (MS) and clinically isolated syndromes (CIS) as quantified using [(11)C](R)-PK11195 positron emission tomography (PET) scanning
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Natalizumab
Integrin alpha-4/beta-1 inhibitor|Integrin alpha-4/beta-7 inhibitor
What it measured
Main measures
The identification of 11C-PK11195 binding potential in cortical areas correspondent to B-cell follicles and the changes in the extent of 11C-PK11195 binding potential in the grey matter over one year in the presence of Tysabri therapy.
Immune response
Who could take part
Early (CIS/RIS)
Inclusion: Patients must have a confirmed diagnosis of multiple sclerosis or clinically isolated syndrome Exclusion: Unable to give informed consent
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To determine the [(11)C](R)-PK11195 identified inflammatory response to natalizumab therapy (Tysabri) in active relapsing remitting MS.
Loading reviews and guidelines…
Related trials
- AttackMS
Phase 2 · Recruiting
Still running
History
Started
Apr 2008
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error